Isiguli sase-Australia Sithola Impendulo Emangalisayo Yasekuqaleni Ngokwelashwa Okubili Kwe-CD19/CD20 CAR-T Kwe-BIOOCUS Medical Group Kwe-DLBCL Ebuye Yaphela
URodney Charles Monger, indoda eneminyaka engu-68 ubudala evela e-Australia, watholakala enesifo esibizwa ngokuthi i-diffuse large. I-B-Cell Lymphoma (DLBCL) eminyakeni emithathu edlule. Efuna ukunakekelwa okuthuthukisiwe, waphendukela ku-BIOOCUS Medical Group ngo-Agasti 2025. I-biopsy ye-lymph node yomlomo wesibeletho yaqinisekisa ukuthi i-B-cell lymphoma ehlaselayo ivela esikhungweni se-germinal center. I-Immunohistochemistry yayine-CD20, CD19, kanye ne-CD10, enokubonakaliswa okuphezulu kwe-Bcl-6, Bcl-2 (70%+), kanye ne-c-MYC (60%+). Ukuhlolwa kwezakhi zofuzo kwembule ukuhlelwa kabusha kwe-BCL2 yi-FISH kanye nokuguqulwa kwezakhi zofuzo ku-EZH2, KMT2D, TNFRSF14, NRAS, kanye ne-TPMT—izimpawu ezicacile zephrofayili enolaka neyingozi enkulu.
Ngemva kokuthola i-pola ehlanganiswe ne-BTK inhibitor kanye ne-lenalidomide, kwalandela i-FC lymphodepletion chemotherapy, isifo sikaMnu. Monger saqhubeka nokungazweli. Ithimba le-BIOOCUS Medical Group lincome ukwelashwa kwabo okusha kwe-CD19/CD20 CAR-T cell okuhloselwe i-dual-targeting.
NgoSepthemba 8, 2025, uMnu. Monger wathola ukufakwa kwamaseli e-CD19/CD20 CAR-T e-autologous. Okuphawulekayo ukuthi akazange abe ne-cytokine release syndrome (CRS) kanye ne-immune effect cell-associated neurotoxicity syndrome (ICANS), okwaholela enkambisweni ebushelelezi ngemuva kokufakwa eyamgcina ezinzile futhi enethemba kusukela ngosuku lokuqala.
Ukuqapha igazi elingaphandle kwaleli gazi kubonise ukwanda okumangalisayo kwamaseli e-CAR-T, okuqinisekisa ukufakwa kanye nokwanda okuhle kakhulu. Ngosuku lwesine ngemuva kokufakwa, amaseli e-CAR19+ ayengu-0.50% wamaseli e-CD3+ T (inani eliphelele 6.04 × 10⁷/L) kanye namaseli e-CAR20+ angu-0.41% (4.96 × 10⁷/L). Ngosuku lwesi-7, i-CAR19+ yakhuphuka yaya ku-1.68% (1.40 × 10⁷/L) kanye ne-CAR20+ yaya ku-1.63% (1.36 × 10⁷/L). Ngosuku lwe-10, i-CAR19+ yafika ku-31.43% wamaseli e-CD3+ T (inani eliphelele 3.13 × 10⁸/L) kanye ne-CAR20+ yafika ku-32.74% (inani eliphelele 3.26 × 10⁸/L). I-Flow cytometry ibonise ukusatshalaliswa okulinganiselayo kuzo zonke izinhlobo ze-CD4+ kanye ne-CD8+ ngokubonakaliswa okunamandla kwe-CAR okukabili, okubonisa ikhono lokwelapha lokukhuthaza ukuqhubeka okuqinile kwe-in-vivo kanye nokwanda kwayo.
Ekulandeleni kwakamuva (usuku lwe-10), uMnu. Monger uyaqhubeka nokwenza kahle ngokwezokwelapha. Usebenzisa umuthi ophuzwayo oklanyelwe wena ohlanganisa i-acyclovir, i-compound sulfamethoxazole, i-orelabrutinib, i-lenalidomide, kanye nemithi esekelayo, ngokuqapha njalo inani legazi, ukusebenza kwesibindi nezinso, kanye nezimpawu zokuvuvukala.
Ithimba le-BIOOCUS Medical Group linikeze ukwesekwa okuphelele, okugxile esigulini kulo lonke, okuhlanganisa indawo yokuhlala ekhululekile, ukudla okunomsoco, usizo lokuhamba, kanye nokwelulekwa kwengqondo kuMnu. Monger nomndeni wakhe. Le ndlela ebanzi yamvumela ukuthi agxile ngokuphelele ekululameni.
Icala likaMnu. Monger libonisa amandla okuguqula ukwelashwa kwe-BIOOCUS Medical Group okubili kwe-CD19/CD20 CAR-T kweziguli ezine-DLBCL ephinde yabuya/engasasebenzi. Ukwanda okusheshayo nokuqinile kwamaseli e-CAR-T ngaphandle kobuthi obukhulu kugqamisa iphrofayili yokuphepha enhle yomkhiqizo kanye nomsebenzi onamandla wokulwa nomdlavuza—ngisho nasesigulini esikhulile esinezici zama-molecule eziyingozi kakhulu.